Daria M. Grousova

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Denis Y. Logunov, Inna V. Dolzhikova, Dmitry V. Shcheblyakov et al. · The Lancet · 2021 · 1.8K citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +16

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Denis Y. Logunov, Inna V. Dolzhikova, Olga V. Zubkova et al. · The Lancet · 2020 · 1.1K citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants

Vladimir А. Gushchin, Inna V. Dolzhikova, Andrei E. Siniavin et al. · Vaccines · 2021 · 119 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults

Amir I. Tukhvatulin, Inna V. Dolzhikova, Dmitry V. Shcheblyakov et al. · The Lancet Regional Health - Europe · 2021 · 71 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals

Daniele Lapa, Daria M. Grousova, Giulia Matusali et al. · Vaccines · 2022 · 37 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +13